Últimos testes


EudraCT Number: 2004-004094-28 Sponsor Protocol Number: D3560L00030 Start Date: 2005-05-20
Sponsor Name: AstraZeneca AB
Full Title: A Randomized, Double-Blind, Placebo Controlled, Multicenter, Phase III Study of Rosuvastatin (CRESTOR) 20 mg in the Primary Prevention of Cardiovascular Events Among Subjects with Low Levels of LDL...
Medical condition: healthy subjects without prior history of MI, stroke or arterial revascularization who, on initial screening, are found to have LDL.C levels below 130 mg/dL (3.36 mmol/L) and CRP levels equal to or...
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: NO (Prematurely Ended) DE (Prematurely Ended) GB (Completed) EE (Prematurely Ended) DK (Prematurely Ended)
Trial results: View results

EudraCT Number: 2004-004439-70 Sponsor Protocol Number: TOC100224 Start Date: 2005-05-20
Sponsor Name: GlaxSmithKline Research & Development
Full Title: A Randomised, Observer-blind, Multicentre, Non-inferiority, Comparative Study of the Safety and Efficacy of Topical 1% SB-275833 Ointment, Applied Twice Daily for 5 Days, versus Topical 2% Sodium F...
Medical condition: Impetigo
Disease: Version SOC Term Classification Code Term Level
7.1 10021531 PT
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
Trial protocol: DE (Completed) IT (Prematurely Ended)
Trial results: View results
EudraCT Number: 2004-005007-14 Sponsor Protocol Number: 20040122 Start Date: 2005-05-20
Sponsor Name: Amgen Inc
Full Title: A Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Palifermin (Recombinant Human Keratinocyte Growth Factor) for Reduction of Oral Mucositis in Subjects Wit...
Medical condition: Oral Mucositis
Disease: Version SOC Term Classification Code Term Level
16.1 100000004856 10028130 Mucositis oral LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: HU (Completed) CZ (Completed) BE (Completed)
Trial results: View results

EudraCT Number: 2004-004162-33 Sponsor Protocol Number: 333369-MIG-2001 Start Date: 2005-05-20
Sponsor Name: Janssen Cilag International NV
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging, Multicenter Study of the Efficacy of RWJ-333369 in the Prophylaxis of Migraine
Medical condition: Migraine headaches
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Male, Female
Trial protocol: DE (Completed)
Trial results: View results
EudraCT Number: 2005-000677-21 Sponsor Protocol Number: CMC-P004 Start Date: 2005-05-20
Sponsor Name: CMC Contrast AB
Full Title: Evaluation of the diagnostic quality of CMC-001 (manganese chloride tetrahydrate) in liver MR-imaging in patients with liver metastases in comparison to Gadolinium BOPTA. A randomised cross-over Ph...
Medical condition: Liver metastases. CMC-001 is an orally administered contrast medium containing manganese (Mn) as the active imaging substance. Manganese is absorbed by the healthy parts of the liver and will thus ...
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: SE (Completed)
Trial results: (No results available)

EudraCT Number: 2004-003735-31 Sponsor Protocol Number: 62179 Start Date: 2005-05-20
Sponsor Name: Gedeon Richter LTD
Full Title: Randomizált, kettős vak, multicentrikus vizsgálat disztális, szenzomotoros típusú diabéteszes neuropátiás fájdalomban az együttesen adott emelkedő dózisú 150 mg-os tolperisone filmtabletta és 30 mg...
Medical condition: Disztális-szenzomotoros típusú diabéteszes neuropátiás fájdalom
Disease: Version SOC Term Classification Code Term Level
7.1 10012680 PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: HU (Ongoing)
Trial results: (No results available)
EudraCT Number: 2005-000689-38 Sponsor Protocol Number: MUCOSITIS/01/2004 Start Date: 2005-05-19
Sponsor Name: Institut Català d’Oncologia
Full Title: ESTUDIO FASE III, ALEATORIZADO, DOBLE CIEGO DE TRATAMIENTO DE LA MUCOSITIS ORAL CON COCIMIENTO DE LLANTÉN VS CLORHEXIDINA AL 0,12% VS DISOLUCIÓN ACUOSA DE BICARBONATO AL 5% EN PACIENTES ONCOLÓGICOS...
Medical condition: Mucositis secundaria a quimioterapia
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: ES (Ongoing)
Trial results: (No results available)

EudraCT Number: 2004-000596-34 Sponsor Protocol Number: WX17798 Start Date: 2005-05-19
Sponsor Name: F.Hoffmann-La Roche Ltd.
Full Title: A prospective, randomized, double-blind, placebo controlled, parallel group, multicenter, 36-weeks trial to assess the efficacy and safety of adjunct mycophenolate mofetil (MMF) to maintain or impr...
Medical condition: Myasthenia gravis
Disease: Version SOC Term Classification Code Term Level
7.1 10028417 LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: CZ (Completed) HU (Completed) IT (Completed) ES (Completed)
Trial results: View results
EudraCT Number: 2005-001499-10 Sponsor Protocol Number: CO34 Start Date: 2005-05-19
Sponsor Name: Dr. José Ramón Mel Lorenzo
Full Title: 'Pilot trial of Pegilated Liposomal Doxorrubicin (Caelyx) in combination with Docetaxel (Taxotere) in advanced breast cancer patients' Estudio Piloto de Doxorrubicina Liposomal Pegilada (Caelyx) en...
Medical condition: Advanced Breast Cancer
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults Gender: Female
Trial protocol: ES (Ongoing)
Trial results: (No results available)

EudraCT Number: 2005-000934-19 Sponsor Protocol Number: 2005-130 Start Date: 2005-05-19
Sponsor Name: Neurologisk Afdeling Århus Universitetshospital
Full Title: Undersøgelse af subcutan immunglobulin behandling af patienter med multifokal motorisk neuropati
Medical condition: Multifokal motor neuropathy
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DK (Completed)
Trial results: (No results available)
3